Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1991 Jul;73(3):264–270.

C3- and T-cell-dependent adjuvant activity of in vivo formed immune complexes.

C W Van den Berg 1, M A Hazenberg 1, F M Hofhuis 1, S M Van Rooyen 1, H Van Dijk 1
PMCID: PMC1384540  PMID: 1879875

Abstract

The effects of polyclonal antibodies to mouse serum components on the primary humoral immune response of mice in vivo were studied. It was observed that rabbit IgG to complement component C3 and albumin and mouse IgG to C5, but also heat-aggregated non-immune rabbit IgG, enhanced the agglutinating antibody response to sheep erythrocytes (SRBC). Since the increase in response was only observed when antigen and antibodies were administered via the same route (i.p.), immunological adjuvant activity was implicated. Ineffectiveness of anti-C5 IgG in C5-deficient mice indicated that the antibody-induced adjuvant activity is mediated by in vivo formed immune complexes (IC). The adjuvant activity of IC was reduced by selective C3-depletion of animals, pointing to a requirement of C3. The effect of variations in other parameters was studied with anti-C3 and anti-C5 IgG as immunoadjuvant. The immunostimulatory effect was most pronounced when the antibodies were administered simultaneously with or shortly before antigen. Treatment of animals with antibodies one or two days before antigen, however, resulted in a suppression of the response. The response to thymus-independent antigens was not enhanced by anti-C3 nor by anti-C5 IgG. Optimal adjuvant activity of anti-C3 IgG was observed at low antigen doses. Nude mice were insensitive to the immunopotentiating effect of anti-C3 and so was the F1 progeny of BALB/c male and CBA/N female mice expressing a B-cell maturation defect. C5 deficiency and lipopolysaccharide (LPS) non-responsiveness did not affect the adjuvant activity of in vivo formed C3-anti-C3 IC.

Full text

PDF
264

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker P. J., Stashak P. W., Prescott B. Use of erythrocytes sensitized with purified pneumococcal polysaccharides for the assay of antibody and antibody-producing cells. Appl Microbiol. 1969 Mar;17(3):422–426. doi: 10.1128/am.17.3.422-426.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beukelman C. J., Aerts P. C., Van Dijk H., Willers J. M. A one-step isolation procedure for phospholipase A2-free cobra venom factor by fast protein liquid chromatography. J Immunol Methods. 1987 Feb 26;97(1):119–122. doi: 10.1016/0022-1759(87)90113-x. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Butman B. T., Jacobsen T., Cabatu O. G., Bourguignon L. Y. The involvement of cAMP in lymphocyte capping. Cell Immunol. 1981 Jul 1;61(2):397–403. doi: 10.1016/0008-8749(81)90387-7. [DOI] [PubMed] [Google Scholar]
  5. Böttger E. C., Metzger S., Bitter-Suermann D., Stevenson G., Kleindienst S., Burger R. Impaired humoral immune response in complement C3-deficient guinea pigs: absence of secondary antibody response. Eur J Immunol. 1986 Oct;16(10):1231–1235. doi: 10.1002/eji.1830161008. [DOI] [PubMed] [Google Scholar]
  6. Carter R. H., Spycher M. O., Ng Y. C., Hoffman R., Fearon D. T. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol. 1988 Jul 15;141(2):457–463. [PubMed] [Google Scholar]
  7. Collisson E. W., Anderson B., Rönnholm M., Lamon E. W. Potentiation of antibody responses by specific IgM: specificity and thymus dependency. Cell Immunol. 1983 Jul 1;79(1):44–55. doi: 10.1016/0008-8749(83)90049-7. [DOI] [PubMed] [Google Scholar]
  8. Coulie P. G., Van Snick J. Enhancement of IgG anti-carrier responses by IgG2 anti-hapten antibodies in mice. Eur J Immunol. 1985 Aug;15(8):793–798. doi: 10.1002/eji.1830150810. [DOI] [PubMed] [Google Scholar]
  9. Daha M. R., Bloem A. C., Ballieux R. E. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol. 1984 Mar;132(3):1197–1201. [PubMed] [Google Scholar]
  10. Dukor P., Hartmann K. U. Hypothesis. Bound C3 as the second signal for B-cell activation. Cell Immunol. 1973 Jun;7(3):349–356. doi: 10.1016/0008-8749(73)90199-8. [DOI] [PubMed] [Google Scholar]
  11. Frade R., Crevon M. C., Barel M., Vazquez A., Krikorian L., Charriaut C., Galanaud P. Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule. Eur J Immunol. 1985 Jan;15(1):73–76. doi: 10.1002/eji.1830150114. [DOI] [PubMed] [Google Scholar]
  12. Hatzfeld A., Fischer E., Levesque J. P., Perrin R., Hatzfeld J., Kazatchkine M. D. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line. J Immunol. 1988 Jan 1;140(1):170–175. [PubMed] [Google Scholar]
  13. Heyman B., Andrighetto G., Wigzell H. Antigen-dependent IgM-mediated enhancement of the sheep erythrocyte response in mice. Evidence for induction of B cells with specificities other than that of the injected antibodies. J Exp Med. 1982 Apr 1;155(4):994–1009. doi: 10.1084/jem.155.4.994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Heyman B., Pilström L., Shulman M. J. Complement activation is required for IgM-mediated enhancement of the antibody response. J Exp Med. 1988 Jun 1;167(6):1999–2004. doi: 10.1084/jem.167.6.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Heyman B. The immune complex: possible ways of regulating the antibody response. Immunol Today. 1990 Sep;11(9):310–313. doi: 10.1016/0167-5699(90)90126-t. [DOI] [PubMed] [Google Scholar]
  16. Heyman B., Wiersma E. J., Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med. 1990 Aug 1;172(2):665–668. doi: 10.1084/jem.172.2.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jungi T. W., Pepys M. B. Delayed hypersensitivity reactions to Listeria monocytogenes in rats decomplemented with cobra factor and in C5-deficient mice. Immunology. 1981 Jun;43(2):271–279. [PMC free article] [PubMed] [Google Scholar]
  18. Klerx J. P., Van Dijk H., Damen H., Rademaker P. M., Willers J. M. Effects of immunological adjuvants on the mouse complement system. I. The inability of the polyanion heparin to act as an adjuvant is paralleled by inefficient alternative complement pathway inhibition. Int J Immunopharmacol. 1983;5(6):549–553. doi: 10.1016/0192-0561(83)90048-6. [DOI] [PubMed] [Google Scholar]
  19. Klerx J. P., van Oosterhout J. M., van Dijk H., Kouwenberg E. A., Willers J. M. Anti-complementary amines are immunological adjuvants in mice. Immunol Lett. 1985;10(5):281–286. doi: 10.1016/0165-2478(85)90102-6. [DOI] [PubMed] [Google Scholar]
  20. Kondo M., Kato H., Yoshikawa T., Sugino S. Immunomodulators and the complement system. Methods Find Exp Clin Pharmacol. 1986 Feb;8(2):67–72. [PubMed] [Google Scholar]
  21. Lernhardt W., Raschke W. C., Melchers F. Alpha-type B cell growth factor and complement component C3: their possible structural relationship. Curr Top Microbiol Immunol. 1986;132:98–104. doi: 10.1007/978-3-642-71562-4_13. [DOI] [PubMed] [Google Scholar]
  22. Melchers F., Erdei A., Schulz T., Dierich M. P. Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature. 1985 Sep 19;317(6034):264–267. doi: 10.1038/317264a0. [DOI] [PubMed] [Google Scholar]
  23. Morgan E. L., Weigle W. O. Biological activities residing in the Fc region of immunoglobulin. Adv Immunol. 1987;40:61–134. doi: 10.1016/s0065-2776(08)60238-2. [DOI] [PubMed] [Google Scholar]
  24. Nemerow G. R., McNaughton M. E., Cooper N. R. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol. 1985 Nov;135(5):3068–3073. [PubMed] [Google Scholar]
  25. O'Neil K. M., Ochs H. D., Heller S. R., Cork L. C., Morris J. M., Winkelstein J. A. Role of C3 in humoral immunity. Defective antibody production in C3-deficient dogs. J Immunol. 1988 Mar 15;140(6):1939–1945. [PubMed] [Google Scholar]
  26. Pepys M. B. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med. 1974 Jul 1;140(1):126–145. doi: 10.1084/jem.140.1.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pepys M. B. Role of complement in induction of the allergic response. Nat New Biol. 1972 May 31;237(74):157–159. doi: 10.1038/newbio237157a0. [DOI] [PubMed] [Google Scholar]
  28. Pepys M. B. Role of complement in the induction of immunological responses. Transplant Rev. 1976;32:93–120. doi: 10.1111/j.1600-065x.1976.tb00230.x. [DOI] [PubMed] [Google Scholar]
  29. Pepys M. B., Taussig M. J. Complement-independence of tolerance induction. Eur J Immunol. 1974 May;4(5):349–352. doi: 10.1002/eji.1830040508. [DOI] [PubMed] [Google Scholar]
  30. Scher I. The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunity. Adv Immunol. 1982;33:1–71. doi: 10.1016/s0065-2776(08)60834-2. [DOI] [PubMed] [Google Scholar]
  31. Van den Berg C. W., Aerts P. C., Van Dijk H. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system. J Immunol Methods. 1990 Oct 19;133(2):199–206. doi: 10.1016/0022-1759(90)90360-8. [DOI] [PubMed] [Google Scholar]
  32. Van den Berg C. W., Aerts P. C., Van Dijk H. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje. J Immunol Methods. 1991 Feb 15;136(2):287–294. doi: 10.1016/0022-1759(91)90015-8. [DOI] [PubMed] [Google Scholar]
  33. Van den Berg C. W., Van Dijk H., Capel P. J. Rapid isolation and characterization of native mouse complement components C3 and C5. J Immunol Methods. 1989 Aug 15;122(1):73–78. doi: 10.1016/0022-1759(89)90336-0. [DOI] [PubMed] [Google Scholar]
  34. Weiss L., Delfraissy J. F., Vazquez A., Wallon C., Galanaud P., Kazatchkine M. D. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J Immunol. 1987 May 1;138(9):2988–2993. [PubMed] [Google Scholar]
  35. Wilson B. S., Platt J. L., Kay N. E. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood. 1985 Oct;66(4):824–829. [PubMed] [Google Scholar]
  36. Yokochi T., Inoue Y., Kimura Y., Kato N. Strong interaction of lipopolysaccharides possessing the mannose homopolysaccharides with complement and its relation to adjuvant action. J Immunol. 1990 Apr 15;144(8):3106–3110. [PubMed] [Google Scholar]
  37. van Dam A. P., Hack C. E. Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement. Immunology. 1987 Jun;61(2):105–110. [PMC free article] [PubMed] [Google Scholar]
  38. van Dijk H., Rademaker P. M., Klerx J. P., Beukelman C. J., Willers J. M. A new, sensitive assay to determine immunological adjuvant activity based on the immunogenicity of neuraminidase-treated sheep erythrocytes. Methods Find Exp Clin Pharmacol. 1986 Mar;8(3):189–193. [PubMed] [Google Scholar]
  39. van den Berg C. W., van Horssen P. J., Hofhuis F. M., Aerts P. C., van Dijk H. C5 does not play a major role in the immune response of mice to SRBC in vivo. Scand J Immunol. 1991 May;33(5):621–626. doi: 10.1111/j.1365-3083.1991.tb02534.x. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES